Moderna Inc. stocks have been trading up by 16.03 percent amid highly positive sentiment around its latest mRNA vaccine advances.
What Traders Need To Know
- Q1 2026 revenue came in at $389M, roughly triple year-over-year and well above the $236.4M consensus, though a $0.9B litigation charge drove about a $1.3B GAAP net loss.
- Management reaffirmed guidance for up to 10% revenue growth in 2026 versus 2025 and projected year-end 2026 cash and investments of $4.5B–$5.0B after continued R&D spend and the settlement.
- Shares gained roughly 3%–8% in early trading after the narrower-than-expected Q1 loss and stronger revenue, helped by international COVID-19 vaccine partnerships.
- The company emphasized EU approval of its flu + COVID combo vaccine mCOMBRIAX and progress across infectious disease, oncology (intismeran/mRNA-4157), norovirus, and late-stage rare-disease programs.
- Major banks including RBC Capital, Goldman Sachs, Evercore ISI, UBS, and Morgan Stanley raised price targets on MRNA post-Q1, while keeping neutral-style ratings and highlighting pipeline catalysts as key drivers.
Weekly Update May 04 – May 08, 2026: On Saturday, May 09, 2026 Moderna Inc. stock [NASDAQ: MRNA] is trending up by 16.03%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Healthcare industry expert:
Analyst sentiment – positive
Moderna’s fundamentals reflect a transition phase from pandemic windfall to a diversified vaccine and oncology platform with currently weak earnings power. Q1 revenue of $389M annualizes well below the $1.94B TTM figure, with gross margin negative and EBITDA margin about -132%, highlighting subscale manufacturing and mix. Yet balance sheet strength is clear: ~$5.2B cash and investments, current ratio 3.3, low debt (D/E 0.15) and price-to-book ~2.2. Sustained negative free cash flow (~$692M) remains the key risk.
Technically, the dominant near-term trend is bullish with clear momentum acceleration. This week’s move from a ~46.5–49.5 range into a strong breakout close at 56.32, on expanding volume, confirms buyers in control and validates the recent sequence of higher highs and higher lows on the weekly chart. A precise actionable level is $50–51, now a key support zone where prior resistance and congestion converge; dips toward this band offer a defined-risk entry, with stops below $48.
More Breaking News
- NOK Stock Slides As Earnings Strength Fails To Impress Traders
- GPN Stock Jumps As Wall Street Ups Price Targets
- NU Stock Plunges Nearly 20% As Volatility Spikes
- Micron Stock Slides As China’s CXMT DRAM Threat Rattles Traders
Catalysts skew favorably versus biotech benchmarks: Moderna just delivered a substantial Q1 beat, reaffirmed 2026 growth, and secured EU approval for mCOMBRIAX plus broader respiratory and oncology progress, while peers face similar R&D burn but weaker balance sheets. Multiple neutrally rated brokers have raised targets into the mid-to-high $40s, and potential FDA leadership change could incrementally ease regulatory overhangs. I view fair value toward $60–65 over 12–18 months, with support near $50 and resistance around $60.
Quick Financial Overview
Moderna Inc. posted Q1 2026 revenue of $389M, a sharp rebound that more than tripled year-over-year and easily cleared the $236.4M consensus bar. Despite this, the company reported a GAAP net loss of about $1.3B, mainly due to a $0.9B one-off litigation settlement, which is important context for traders scanning the headline loss. Under the surface, gross margin of 55.7% and a still-heavy R&D line show a business investing hard into its pipeline rather than managing for near-term profitability.
From a balance sheet angle, Moderna Inc. remains well capitalized. Cash, cash equivalents, and short-term investments sit above $5.2B, and management expects to finish 2026 with $4.5B–$5.0B even after the settlement and planned R&D of roughly $3B. Low leverage, with total debt-to-equity around 0.15 and strong liquidity ratios, reduces near-term financing risk. For traders, that means dilution pressure is not the core story right now; the key variable is whether the pipeline can convert into durable revenue.
On the tape, the weekly chart for MRNA shows a strong momentum push. Price bounced from the mid-$40s early in the week and spiked to the mid-$50s, closing near $56.32, which marks a clear breakout versus recent opens around $47–$49. Intraday, a single wide-range candle shows a surge from roughly $49.29 to an intraday high near $57.78 before closing at $54.35, signaling aggressive buying and then some profit-taking. With a price-to-sales ratio near 9.8 on trailing revenue of about $1.94B, the market is already pricing in meaningful future growth, so any disappointment on upcoming oncology or combo-vaccine data could hit the stock hard.
Conclusion
This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.
Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.
Check out our quick startup guide for new traders!
- How to Read Stock Charts: A Guide for Beginners
- Trading Plan: 6 Steps to Create One
- How To Create a Stock Watchlist
Ready to build your watchlists? Check out these curated lists:
Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.